Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) Daniel G. Coit et al.   Journal of the National Comprehensive Cancer Network

Severe Gastrointestinal Toxicity of MEK Inhibitors

(2019) Nadim Mourad et al.   MELANOMA RESEARCH

Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review

(2019) Qingliang Yu et al.   Cancer Medicine

Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors

(2018) Mohd Wahid et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients

(2018) Jacek Mackiewicz et al.   Wspolczesna Onkologia-Contemporary Oncology

Increased Apoptosis in the Paraventricular Nucleus Mediated by AT1R/Ras/ERK1/2 Signaling Results in Sympathetic Hyperactivity and Renovascular Hypertension in Rats after Kidney Injury

(2017) Hongguo Zhu et al.   Frontiers in Physiology

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data

(2015) O. Abdel-Rahman et al.   Clinical & Translational Oncology

BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma

(2015) Juliet Richman et al.   EXPERT OPINION ON PHARMACOTHERAPY

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials

(2015) Ruiqin Mai et al.   Oncotarget

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

(2015) Zeynep Eroglu et al.   Therapeutic Advances in Medical Oncology

Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

(2014) Giuseppe Bronte et al.   Expert Opinion On Drug Safety

Combined inhibition of BRAF and MEK in melanoma patients

(2014) Jeffrey R Infante et al.   LANCET ONCOLOGY

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma

(2014) Clara I. Lee et al.   MELANOMA RESEARCH

Mutations of theBRAFgene in human cancer, by Davieset al. (Nature2002; 417: 949-54)

(2013) G. W. M. Millington   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE